Phase 2 Macular Degeneration Trial, Recruiting NCT06672536 Sponsor: Sinocelltech Ltd. Condition: Macular Degeneration
Back to Macular Degeneration

Phase 2 Macular Degeneration Trial, Recruiting

NCT06672536
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form to take part in the study
  • You are between 45 and 80 years old (male or female)
  • Your eye being studied has been diagnosed with a condition called "wet" age-related macular degeneration (nAMD)
  • There is currently active abnormal blood vessel growth in the eye being studied, related to wet AMD
  • The total size of the affected area in the eye being studied is within a certain limit (confirm with trial site)
  • Your vision in the eye being studied falls within a specific range on a standard eye test (confirm with trial site)

Who may not be able to join:

  • The eye being studied has tears, scarring, fibrosis, tissue loss, or heavy fluid buildup affecting the central part of the retina
  • The eye being studied has cloudiness, a pupil that won't open properly, or other issues that block a clear view of the eye or affect vision
  • The eye being studied is missing its natural lens and does not have an artificial lens, or has a specific type of lens damage (confirm with trial site)
  • The eye being studied has any other eye condition or history of eye disease — apart from wet AMD — that could affect central vision or eye examination results
  • The abnormal blood vessel growth in the eye being studied is caused by something other than wet AMD
  • Either eye has active inflammation or infection at the time of joining the trial
  • You have a known allergy to any ingredient in the study treatment, or to the dyes or medicines used during eye examinations and procedures in this study
  • You have abnormal liver or kidney function
  • Your blood pressure is not well controlled at the time of joining the trial
  • You have had a serious heart or blood vessel event — such as a heart attack, unstable chest pain, stroke, mini-stroke (TIA), or blood clot-related condition — within the 6 months before joining
  • You have another serious ongoing illness that is not well controlled
  • You have taken part in another clinical trial involving a drug or medical device within the past 3 months (or longer, depending on the previous study drug)
  • You are pregnant, breastfeeding, or are unable to use contraception during the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86-18626789043

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Sinocelltech Ltd.
Registry
ClinicalTrials.gov
Start date
26 November 2024
Est. completion
23 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Treatment emergent adverse events(TEAE); Treatment-related treatment emergent adverse events(TRAE); Serious adverse event(SAE); Adverse event of special interest(AESI); Dose limited toxicity(DLT)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov